GS:" M&amp;A signals from large biopharma acquirers are picking up again with Sanofi highlighting gene therapy interest, $MRK
suspending its buyback to target other priorities including BD, and $PFE reiterating appetite for Ph2/3 assets while noting valuations of some biotechs..."